The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas

Authors: Khamly, Kenneth K; Hicks, Rodney J; McArthur, Grant A; Thomas, David M

Source: Expert Review of Molecular Diagnostics, Volume 8, Number 1, January 2008 , pp. 105-119(15)

Publisher: Expert Reviews

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

Positron emission tomography (PET) is a noninvasive functional imaging technique that allows assessment of key biological processes important in cancer development and progression. It provides information complementary to conventional anatomic imaging, demonstrating utility in a range of cancer settings from diagnosis, biopsy guidance, tumor stratification and prognostication, and staging and surveillance of disease recurrence. Its ability to evaluate vital processes in tumor biology also makes it a potentially valuable and sensitive tool for assessing therapeutic response. The development of novel PET tracers and improvements in technology will only continue to augment the potential of PET and enhance its attractiveness as an instrument to facilitate drug development. This article will discuss the above issues, using the setting of sarcomas as an example.

Keywords: drug development; hypoxia; PET; positron emission tomography; sarcoma; therapeutic response; tumor metabolism

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737159.8.1.105

Affiliations: 1: Division of Haematology & Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia., Email: ken.khamly@petermac.org

Publication date: 2008-01-01

More about this publication?
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page